Literature DB >> 14663479

Myc pathways provoking cell suicide and cancer.

Jonas A Nilsson1, John L Cleveland.   

Abstract

A paradox for the cancer biology field has been the revelation that oncogenes, once thought to simply provide advantages to a cancer cell, actually put it at dire risk of cell suicide. Myc is the quintessential oncogene in this respect, as in normal cells it is required for cell cycle traverse, whereas in cancers it is overexpressed and functions as the angiogenic switch. Nonetheless, Myc overexpression kills normal cells dead in their tracks. Here we review Myc-induced pathways that contribute to the apoptotic response. Molecular analysis of Myc-induced tumors has established that some of these apoptotic pathways are essential checkpoints that guard the cell from cancer, as they are selectively bypassed during tumorigenesis. The precise mechanism(s) by which Myc targets these pathways are largely unresolved, but we propose that they involve crosstalk and feedback regulatory loops between arbiters of cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663479     DOI: 10.1038/sj.onc.1207261

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  180 in total

1.  In silico identification of transcriptional regulators associated with c-Myc.

Authors:  Ran Elkon; Karen I Zeller; Chaim Linhart; Chi V Dang; Ron Shamir; Yosef Shiloh
Journal:  Nucleic Acids Res       Date:  2004-09-23       Impact factor: 16.971

2.  c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation.

Authors:  Anne Wilson; Mark J Murphy; Thordur Oskarsson; Konstantinos Kaloulis; Michael D Bettess; Gabriela M Oser; Anne-Catherine Pasche; Christian Knabenhans; H Robson Macdonald; Andreas Trumpp
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

3.  Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex.

Authors:  Robert V Brown; Forest L Danford; Vijay Gokhale; Laurence H Hurley; Tracy A Brooks
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

4.  The impact of C-MYC gene expression on gastric cancer cell.

Authors:  Lin Zhang; Yanhong Hou; Hassan Ashktorab; Liucun Gao; Yanjie Xu; Kai Wu; Junshan Zhai; Lei Zhang
Journal:  Mol Cell Biochem       Date:  2010-08-25       Impact factor: 3.396

5.  C-Myc is a Nrf2-interacting protein that negatively regulates phase II genes through their electrophile responsive elements.

Authors:  Smadar Levy; Henry Jay Forman
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

6.  Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Authors:  Kristopher A Sarosiek; Lucas E Cavallin; Shruti Bhatt; Ngoc L Toomey; Yasodha Natkunam; Wilfredo Blasini; Andrew J Gentles; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

7.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

Authors:  Charles Keller; Benjamin R Arenkiel; Cheryl M Coffin; Nabeel El-Bardeesy; Ronald A DePinho; Mario R Capecchi
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

8.  MYC needs MNT.

Authors:  Jason M Link; Peter J Hurlin
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

9.  IL-6 and MYC collaborate in plasma cell tumor formation in mice.

Authors:  Sebastian Rutsch; Vishala T Neppalli; Dong-Mi Shin; Wendy DuBois; Herbert C Morse; Hartmut Goldschmidt; Siegfried Janz
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

10.  Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.

Authors:  E M Michalak; E S Jansen; L Happo; M S Cragg; L Tai; G K Smyth; A Strasser; J M Adams; C L Scott
Journal:  Cell Death Differ       Date:  2009-01-16       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.